D3
VC Fund
Tokyo, Japan
D3 is a VC fund in Tokyo focused on Biotechnology and Therapeutics. D3 LLC is providing management consultancy and financial services.
- Total investments:
- 12
- Last investment:
- Lead investor:
- 58%
Last updated:
For AI agents: llms.txt
Industries D3 invests in
Stages D3 invests in
Countries D3 invests in
Round sizes
Round size
- Seed
- $1.6M–$2.8M
- Series A
- $690k–$51M
Investment Focus
Industry
- Biotechnology 4 (33%)
- Therapeutics 3 (25%)
- Manufacturing 3 (25%)
- Medical 2 (17%)
- Software 2 (17%)
Stage
- Series A 6 (50%)
- Seed 3 (25%)
- Series B 1 (8%)
Country
- Japan 6 (50%)
- United States 2 (17%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Neumo is a musical education-based firm that offers pitch measurement courses, programs, consulting, and tests. | Series A / Apr 23, 2026 | ||
| RevolKa manufactures bio-products pharmaceuticals intended to serve the healthcare sector. | $1.5M / Series A / May 20, 2025 | ||
| Neros Technologies is a defense technology company specializing in the development and manufacturing of advanced unmanned aerial systems (UAS). The Neros Archer, the company's flagship product, is a high-performance, long-range First-Person View (FPV) drone certified by BlueUAS. Designed for large-scale deployment, it is optimized forlong-range missions with resistance to electronic warfare and can carry a 2 kg (approximately 4.5 lbs) payload over a distance of 20 kilometers. | $35M / Series A / Mar 17, 2025 | ||
| Alpha Fusion produces astatine based radiopharmaceuticals for targeted alpha therapy. | $6.9M / Series B / Oct 08, 2024 | ||
| Swarmer is an AI based mission control center for coordinated drones that acts as Firmware for video streaming, logging and monitoring. | $2.7M / Seed / Sep 01, 2024 | ||
| RevolKa manufactures bio-products pharmaceuticals intended to serve the healthcare sector. | $690.2K / Series A / Aug 29, 2024 | ||
| Cyto-Facto is a biotechnology company that develops and manufactures CAR-T cell therapies and mesenchymal stem cell products. | $7.6M / Series A / Apr 22, 2024 | ||
| RevolKa manufactures bio-products pharmaceuticals intended to serve the healthcare sector. | $1M / Series A / Feb 01, 2024 | ||
| Shinobi Therapeutics is a biotechnology business that is working on a novel class of immune-evasive iPSC-derived cell treatments. | $51M / Series A / Dec 12, 2023 | ||
| B4A provides DX tool for medical clinics that helps with reservation, customer management, and data analysis. | $2M / Series A / Sep 27, 2023 | ||
| See all 12 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does D3 invest in?
D3 invests primarily in Biotechnology, Therapeutics and Manufacturing startups, most often at Series A and Seed stage. Most of the 12 investments tracked by Shizune back companies in Japan. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is D3's check size?
D3 typically joins rounds of $1.6M–$2.8M at Seed and $690k–$51M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds D3 participates in.
When did D3 last invest?
The most recent investment recorded for D3 closed in Apr 2026. Shizune tracks 12 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
